Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Status:
Closed
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
S1613, Step 3 (optional crossover) is permanently closed to accrual, effective November 30, 2023 at 11:59pm Pacific Time
S1613, Step 2 (randomization) is permanently closed to accrual, effective March 31, 2022.
S1613 is permanently closed to accrual, effective December 31, 2021.
NCT#03365882
